Vertaling van "medicinal products of " (Nederlands → Frans) :

TERMINOLOGIE

product dat aescine bevat
produit contenant de l'aescine

product dat balsalazide bevat
produit contenant du balsalazide

product dat bacitracine bevat
produit contenant de la bacitracine

product dat barbituraat bevat
produit contenant du barbiturique

product dat basiliximab bevat
produit contenant du basiliximab

product dat baclofen bevat
produit contenant du baclofène

product dat auranofine bevat
produit contenant de l'auranofine

product dat auranofine in orale vorm bevat
produit contenant de l'auranofine sous forme orale

product dat enkel auranofine in orale vorm bevat
produit contenant seulement de l'auranofine sous forme orale

product dat baricitinib bevat
produit contenant du baricitinib

IN-CONTEXT TRANSLATIONS

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products Royal decrees of 25 February 2007 on the composition and working method of the committees of the Federal Agency for Medicines and Health Products Royal decree of 20 December 2007 determining the date of establishment of the Scientific Committee, namely 1 February 2008 Royal decree of 28 January 2008 on the concrete composition of the Consultative Committee Ministerial decree of 11 January 2007 on the composition and appointment of the members of the executive board of the Federal Agency for Medicines and Health Products
Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products Royal decrees of 25 February 2007 on the composition and working method of the committees of the Federal Agency for Medicines and Health Products Royal decree of 20 December 2007 determining the date of establishment of the Scientific Committee, namely 1 February 2008 Royal decree of 28 January 2008 on the concrete composition of the Consultative Committee Ministerial decree of 11 January 2007 on the composition and appointment of the members of the executive board of the Federal Agency for Medicines and Health Products

Thus the FAHMP inspectors in the Production & Distribution department have a duty to control the relevant industry (medicines and health products), the blood establishments, the cell and tissue banks, the wholesale trade of medicines and health products, the retail and hospital pharmacies and the stocks of medicines at the veterinarians.
Thus the FAHMP inspectors in the Production & Distribution department have a duty to control the relevant industry (medicines and health products), the blood establishments, the cell and tissue banks, the wholesale trade of medicines and health products, the retail and hospital pharmacies and the stocks of medicines at the veterinarians.

Advies van 21/09/2012 (PDF, 158.49 Kb) met betrekking tot " ethanol content in medicinal products used in children (including herbal medicinal products and homeopathic medicinal products)" (English version).
Avis du 21/09/2012 (PDF, 158.49 Kb) concernant l'" ethanol content in medicinal products used in children (including herbal medicinal products and homeopathic medicinal products )" (english version).

Herbal medicinal products In line with the provisions of the royal decree of 14 December 2006, three procedures are used for the issue of the MA or registration for herbal medicinal products: the full procedure, the “Well Established Use” procedure and a third specific procedure for traditional herbal medicines as stipulated in article 43 of the royal decree.
Herbal medicinal products In line with the provisions of the royal decree of 14 December 2006, three procedures are used for the issue of the MA or registration for herbal medicinal products: the full procedure, the “Well Established Use” procedure and a third specific procedure for traditional herbal medicines as stipulated in article 43 of the royal decree.

Borderline products and medicines without a market authorisation The trade in traditional medicines such as TCM (Traditional Chinese Medicines, Ayurveda and others) The theft of medicines and their resale on the black market
Borderline products and medicines without a market authorisation The trade in traditional medicines such as TCM (Traditional Chinese Medicines, Ayurveda and others) The theft of medicines and their resale on the black market

De documenten zijn vrij raadpleegbaar op de website van de EMA: www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/landing/herbal_ search.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001fa1d Bij de evaluatie van kruiden of herbal substances die in aanmerking komen als geneesmiddelen of herbal medicinal products spelen kwaliteit, veiligheid en doeltreffendheid een rol.
Les documents peuvent être consultés librement sur le site Web de l’EMA: www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/landing/ herbal_search.jsp&murl=menus/medicines/ medicines. jsp&mid=WC0b01ac058001fa1d L’évaluation des plantes (ou herbal substances) qui entrent en ligne de compte comme médicaments (ou herbal medicinal products) se penche sur leur qualité, innocuité et efficacité.

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

Naar aanleiding van deze gegevens kreeg het Committee for Proprietary Medicinal Products (CPMP), het wetenschappelijk adviesorgaan van het European Agency for the Evaluation of Medicinal Products, de opdracht de baten-risicoverhouding van de hierboven vermelde anorexigenen opnieuw te evalueren.
Prenant en compte ces données, le Comité des Spécialités Pharmaceutiques (CSP), l’organe scientifique de l' Agence Européenne pour l’évaluation des Médicaments, a été chargé de procéder à une réévaluation de la balance bénéfice/risque des anorexigènes mentionnés ci-dessus.

De gegevens over de veiligheid van aliskiren werden recent herbekeken door het Committee for Medicinal Products for Human Use (CHMP) van het European Medicines Agency (EMA) [ www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/02/WC500122916.pdf ].
Les données concernant le profil d’innocuité de l’aliskirène ont été récemment revues par le Committee for Medicinal Products for Human Use (CHMP) de l’Agence européenne des médicaments (EMA) [ www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/02/ WC500122916.pdf ].